Medical Device and In Vitro Diagnostics/Research Deal Statistics Quarterly, Q3 2010
Executive Summary
Medical device financings during the third quarter of 2010 brought in $997 million, an increase of 82% from the second quarter's $548 million. While Q3 M&A activity was down slightly from last quarter - only 15 mergers were completed, compared with 18 in Q2 - more money was involved: an impressive $6.7 billion. The venture rounds for PacBio and Complete Genomics boosted late-stage VC money to $171 million in the third quarter, two-thirds of the entire amount for the in vitro diagnostics/research industry. Despite only five acquisitions closing during the third quarter, the M&A dollar volume for the IVD/research industry was just north of $2 billion.
You may also be interested in...
Asthmatx Acquisition By Boston Scientific Is Source of Many Happy Returns
Boston Scientific's acquisition of Asthmatx marks a return of the company to the field of strategic buyers with the deal, and in picking Asthmatx, BSX is is reversing a decision it made two years when it sold off its strategic stake in the asthma-device company.
St. Jude Eyes Possible Acquisition Of Heart Failure Monitor Firm CardioMEMS
St. Jude Medical is placing a $60 million bet on wireless implantable heart failure monitor developer CardioMEMS and has acquired an exclusive option to own the entire company via a Sept. 7 agreement
Sanofi-Aventis' Interest In Genzyme May Include Diagnostics Arm
Drug maker Sanofi-Aventis is signaling potential interest in Genzyme's molecular diagnostics business, suggesting that the unit could be retained if Sanofi succeeds in its quest to acquire Genzyme